Switch theme
Sign up to access all valuation multiples
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
2016
13
LTM Revenue $0.1M
Last FY EBITDA -$2.2M
$23.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jupiter Neurosciences has a last 12-month revenue (LTM) of $0.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Jupiter Neurosciences achieved revenue of n/a and an EBITDA of -$2.2M.
Jupiter Neurosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jupiter Neurosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | $0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$2.2M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$5.2M | XXX | -$3.1M | XXX | XXX | XXX |
| EBIT Margin | -7205% | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$4.8M | XXX | -$2.4M | XXX | XXX | XXX |
| Net Margin | -6672% | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Jupiter Neurosciences's stock price is $1.
Jupiter Neurosciences has current market cap of $25.7M, and EV of $23.2M.
See Jupiter Neurosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $23.2M | $25.7M | XXX | XXX | XXX | XXX | $-0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Jupiter Neurosciences has market cap of $25.7M and EV of $23.2M.
Jupiter Neurosciences's trades at n/a EV/Revenue multiple, and -10.6x EV/EBITDA.
Equity research analysts estimate Jupiter Neurosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Jupiter Neurosciences has a P/E ratio of -5.3x.
See valuation multiples for Jupiter Neurosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $25.7M | XXX | $25.7M | XXX | XXX | XXX |
| EV (current) | $23.2M | XXX | $23.2M | XXX | XXX | XXX |
| EV/Revenue | 319.9x | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -10.6x | XXX | XXX | XXX |
| EV/EBIT | -4.4x | XXX | -7.5x | XXX | XXX | XXX |
| EV/Gross Profit | 319.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.3x | XXX | -10.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -5.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialJupiter Neurosciences's last 12 month revenue growth is 6560%
Jupiter Neurosciences's revenue per employee in the last FY averaged n/a, while opex per employee averaged $0.2M for the same period.
Jupiter Neurosciences's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Jupiter Neurosciences's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Jupiter Neurosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 6560% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| LTR Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Starpharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Schott Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanoform | XXX | XXX | XXX | XXX | XXX | XXX |
| Peptron | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jupiter Neurosciences acquired XXX companies to date.
Last acquisition by Jupiter Neurosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Jupiter Neurosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Jupiter Neurosciences founded? | Jupiter Neurosciences was founded in 2016. |
| Where is Jupiter Neurosciences headquartered? | Jupiter Neurosciences is headquartered in United States of America. |
| How many employees does Jupiter Neurosciences have? | As of today, Jupiter Neurosciences has 13 employees. |
| Who is the CEO of Jupiter Neurosciences? | Jupiter Neurosciences's CEO is Mr. Christer Rosen. |
| Is Jupiter Neurosciences publicy listed? | Yes, Jupiter Neurosciences is a public company listed on NAS. |
| What is the stock symbol of Jupiter Neurosciences? | Jupiter Neurosciences trades under JUNS ticker. |
| When did Jupiter Neurosciences go public? | Jupiter Neurosciences went public in 2024. |
| Who are competitors of Jupiter Neurosciences? | Similar companies to Jupiter Neurosciences include e.g. LTR Pharma, Starpharma, Schott Pharma, Nanoform. |
| What is the current market cap of Jupiter Neurosciences? | Jupiter Neurosciences's current market cap is $25.7M |
| What is the current revenue of Jupiter Neurosciences? | Jupiter Neurosciences's last 12 months revenue is $0.1M. |
| What is the current revenue growth of Jupiter Neurosciences? | Jupiter Neurosciences revenue growth (NTM/LTM) is 6560%. |
| What is the current EV/Revenue multiple of Jupiter Neurosciences? | Current revenue multiple of Jupiter Neurosciences is 319.9x. |
| Is Jupiter Neurosciences profitable? | Yes, Jupiter Neurosciences is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
